This trial is evaluating whether 18F- DCFPyL PET/CT will improve 1 primary outcome, 2 secondary outcomes, and 2 other outcomes in patients with Prostate Cancer. Measurement will happen over the course of 3.5 years.
This trial requires 129 total participants across 2 different treatment groups
This trial involves 2 different treatments. 18F- DCFPyL PET/CT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.
Prostate cancer is more common in men of African descent, who have increased risk from the prostate specific antigen assay. This may be because of an increased risk from high levels of prostate specific antigen.
The cure rate of prostate cancer is approximately 75% with curative treatment if all available treatment options are used. Patients with high risk disease tend to have a poor prognosis, and therefore, curative treatment should only be considered for those patients.
Common treatment for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s include surgery, chemotherapy, radiation therapies, or hormonal therapy. There is no one-size-fits-all prostate treatment approach, and the treatment strategy depends on the type and extent of the growth of the tumor.
In men with a family history of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), early referral to a urologist is highly important. These men can benefit from early screening to avoid the inconvenience and anxiety. Prostate-specific antigen testing alone is not reliable enough to predict who will develop cancer. Screening men over the age of 50 years should be offered every 3 years.
If the current prostate cancer detection rates continue to rise, and no appreciable decline occurs in the mortality attributable to prostate cancer, more than 1,000 new cases of prostate cancer will be diagnosed every year.
Many symptoms of PCa and PCa-related symptoms can be mistaken with those of other common conditions, such as BPH and a urinary tract infection. Therefore, a complete history and physical examination can significantly increase the detection of PCa because it can help to distinguish between BPH and PCa.
This case has highlighted uncertainties associated with the use of FDACP PET/CTs, as well as the potential risks of exposing the patient to ionizing radiation. The risk of an incidental finding of prostate cancer has to be considered when patients in good health undergo FDACP PET/CTs.
A single administration of (18)F-dfpyl was well tolerated in patients with prostate cancer. Further studies are needed to understand its clinical impact. (18)F-dfpyl PET/CT may be a useful tool for the identification of clinically insignificant prostate cancer.
If a prostate cancer was not known before the age of 45 to 50 years, the chance of developing a prostate cancer is about 10%. If the prostate cancer is known before the age of 40 to 45 years, the chance of developing a prostate cancer at 45 to 50 years is 2.3%, but this number decreased with time, from 7.8 to 3.3%. After the age of 50 to 55 years, these numbers are lower, between 1.2% and 0.9%. The total number is between 3.4% and 2%, depending on the age of the patient.
Although there are not many publications in the literature concerning the PET/MRI of FDPC, many of these articles suggest the same role as (18)F-DACFPy PET/MRI for the detection of prostate cancer when PET/MRI alone is negative.
Adding 18F-DCPP PET to the clinical workup does not seem to have an impact on the therapeutic decisions. The treatment decision is based on the tumor PET/CT findings alone and not on the 18F-DCPP PET PET/CT results alone.
The present data support the concept of prostate specific membrane antigen-expressing LNCaP cells as a valid model for the metastatic (and possibly prostate specific antigen-expressing) cells and are consistent with the notion that dCF4 is a potential PET-labeled tracer for metastatic cell cancer.